A detailed history of Mercer Global Advisors Inc transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Mercer Global Advisors Inc holds 39,043 shares of APLS stock, worth $793,744. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,043
Previous 20,941 86.44%
Holding current value
$793,744
Previous $362,000 143.92%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$17.42 - $28.65 $315,336 - $518,622
18,102 Added 86.44%
39,043 $883,000
Q2 2025

Aug 14, 2025

SELL
$16.36 - $23.0 $13,431 - $18,883
-821 Reduced 3.77%
20,941 $362,000
Q1 2025

May 15, 2025

BUY
$21.87 - $34.63 $199,651 - $316,137
9,129 Added 72.26%
21,762 $475,000
Q4 2024

Feb 14, 2025

BUY
$26.18 - $35.42 $330,731 - $447,460
12,633 New
12,633 $403,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $2.23B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Mercer Global Advisors Inc Portfolio

Follow Mercer Global Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Mercer Global Advisors Inc with notifications on news.